Scienture Holdings (FRA:4E4) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4E4 Scienture Holdings Inc FRA:4E4
47 GF Score
Price €0.19
GF Value €0.18
! 6 Warning Signs
View Full Analysis

What is Scienture Holdings FFO?

FFO (Funds from operations) only applies to REITs.

FRA:4E4
47GF Score
Scienture Holdings Inc FRA:4E4
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Scienture Holdings (FRA:4E4) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued. The current stock price of €0.19 is trading 7.4% above its estimated GF Value™ of €0.18.

Key valuation signals for FRA:4E4:

  • FFO:
  • GF Value™: €0.18 vs. price of €0.19 (7.4% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the FRA:4E4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scienture Holdings Business Description

Other Exchanges SCNX:USA
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score

Get the complete analysis for FRA:4E4

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.18
GF Value